Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Consolidated Net Income (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Consolidated Net Income readings, the most recent being -$9.0 million for Q4 2024.

  • On a quarterly basis, Consolidated Net Income fell 44.82% to -$9.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$30.9 million, a 52.79% decrease, with the full-year FY2025 number at -$28.6 million, up 7.6% from a year prior.
  • Consolidated Net Income hit -$9.0 million in Q4 2024 for Unicycive Therapeutics, down from -$5.8 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$3.5 million in Q1 2022 to a low of -$9.2 million in Q1 2024.
  • Median Consolidated Net Income over the past 3 years was -$5.6 million (2022), compared with a mean of -$5.8 million.
  • The widest YoY moves for Consolidated Net Income: up 2.11% in 2024, down 117.98% in 2024.
  • Unicycive Therapeutics' Consolidated Net Income stood at -$5.3 million in 2022, then dropped by 16.22% to -$6.2 million in 2023, then plummeted by 44.82% to -$9.0 million in 2024.
  • The last three reported values for Consolidated Net Income were -$9.0 million (Q4 2024), -$5.8 million (Q3 2024), and -$7.0 million (Q2 2024) per Business Quant data.